Literature DB >> 3549105

Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

B N Swerdlow, F O Holley.   

Abstract

The number and variety of intravenous anaesthetics available has increased dramatically in recent years. In order to administer these agents safely and rationally in the operating theatre, the anaesthesiologist needs to have a detailed understanding of their dose-response behaviour. The pharmacokinetic and pharmacodynamic profiles of these anaesthetics underlie this behaviour. In understanding and applying this information, an integrated approach involving combined pharmacokinetic and pharmacodynamic modelling has proved tremendously helpful. This approach has provided significant insight into the pharmacology of these drugs under conditions of normal and abnormal physiology. Intravenous anaesthetics may be classified as hypnotics, narcotics, or muscle relaxants. Through quantitative measures or drug effect, as provided by the electroencephalogram (EEG) in the former two classes or electromyography in the latter class, precise measures of end-organ (brain or neuromuscular junction) sensitivity have been generated using integrated modelling techniques. These values not only allow for dose potency comparisons within an anaesthetic class but, furthermore, may explain changes in drug response with ageing and disease. Incorporation within these models of an effect compartment, characterised by a rate constant for equilibration with plasma (keo), has proved to be essential in accurately describing the temporal lag between drug administration and effect. Quantitating the size of this lag has direct implications for the design of anaesthetic bolus and infusion regimens. Combined pharmacokinetic and pharmacodynamic modelling of intravenous anaesthetics provides a precise, rational basis for the clinical use of these classes of drugs.

Mesh:

Substances:

Year:  1987        PMID: 3549105     DOI: 10.2165/00003088-198712020-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  166 in total

1.  Distribution and biotransformation of succinylcholine.

Authors:  F F Foldes
Journal:  Int Anesthesiol Clin       Date:  1975

Review 2.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of the non-depolarising muscle relaxants.

Authors:  M I Ramzan; A A Somogyi; J S Walker; C A Shanks; E J Triggs
Journal:  Clin Pharmacokinet       Date:  1981 Jan-Feb       Impact factor: 6.447

4.  Comparative pharmacokinetics of fentanyl and alfentanil.

Authors:  S Bower; C J Hull
Journal:  Br J Anaesth       Date:  1982-08       Impact factor: 9.166

5.  The pharmacokinetics of sufentanil in surgical patients.

Authors:  J G Bovill; P S Sebel; C L Blackburn; V Oei-Lim; J J Heykants
Journal:  Anesthesiology       Date:  1984-11       Impact factor: 7.892

6.  Thiopentone sensitivity in young and elderly women.

Authors:  J H Christensen; F Andreasen; J A Jansen
Journal:  Br J Anaesth       Date:  1983-01       Impact factor: 9.166

7.  Effect of preanaesthetic medication on etomidate.

Authors:  M Zacharias; J W Dundee; R S Clarke; J E Hegarty
Journal:  Br J Anaesth       Date:  1979-02       Impact factor: 9.166

8.  Kinetics of drug action in disease states. IV. Effect of pregnancy on phenobarbital concentrations at onset of loss of righting reflex in rats.

Authors:  M Danhof; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1985-02       Impact factor: 4.030

9.  The hemodynamic consequences of high-dose methohexital anesthesia in humans.

Authors:  M M Todd; J C Drummond; H S U
Journal:  Anesthesiology       Date:  1984-11       Impact factor: 7.892

10.  Pharmacodynamic modeling of thiopental anesthesia.

Authors:  D R Stanski; R J Hudson; T D Homer; L J Saidman; E Meathe
Journal:  J Pharmacokinet Biopharm       Date:  1984-04
View more
  9 in total

1.  Do plasma concentrations obtained from early arterial blood sampling improve pharmacokinetic/pharmacodynamic modeling?

Authors:  T M Beaufort; J H Proost; K Kuizenga; M C Houwertjes; U W Kleef; J M Wierda
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

2.  Quantitative determination of atracurium in human plasma using high-performance liquid chromatography.

Authors:  R Okutani; K Kono; F M DeBros; D M Philbin
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

Review 3.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

4.  A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs.

Authors:  F Donati; C Meistelman
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

Review 5.  The use of kinetic-dynamic interactions in the evaluation of drugs.

Authors:  D B Campbell
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 6.  Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.

Authors:  A Van Peer; E Snoeck; M L Huang; J Heykants
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

7.  Non linear disposition of thiopentone following long-term infusion.

Authors:  P Le Corre; Y Malledant; M Tanguy; R Le Verge
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

8.  Difference of train-of-four fade induced by nondepolarizing neuromuscular blocking drugs: a theoretical consideration on the underlying mechanisms.

Authors:  T Tajima; J Amaya; K Katayama; T Koizumi
Journal:  J Anesth       Date:  1995-12       Impact factor: 2.078

Review 9.  Clinical features and management of intoxication due to hallucinogenic drugs.

Authors:  J B Leikin; A J Krantz; M Zell-Kanter; R L Barkin; D O Hryhorczuk
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.